Summary
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic
stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant
recipient) from the mobilized peripheral blood of a specific, unique donor. It is
composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory
T cells (Tregs), and conventional T cells (Tcons) in participants undergoing
myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic
malignancies.